Drugs / SPY001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07652294 | Jun 2026 → Mar 2029 expected | ulcerative colitis | Spyre Therapeutics, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07012395 | May 2025 → Jun 2027 expected | ulcerative colitis | Spyre Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPY001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07652294 ↗ |
| Route | Intravenous | “intravenous (IV) induction” NCT07012395 ↗ |